Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Journal of Clinical Pharmacology|January 23, 2015
Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimodApril M Barbour, Mindy Magee, Bonnie Shaddinger, et al.British Journal of Clinical Pharmacology|May 31, 2017
Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging studySteven Thornton, Guillermo Valenzuela, Charlotte Baidoo, et al.Journal of Clinical Pharmacology|December 7, 2016
Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure ProphylaxisKumpal Madrasi, Ayyappa Chaturvedula, Jessica E Haberer, et al.Journal of Pain Research|October 25, 2017
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplastyNeil Singla, Harold S Minkowitz, David G Soergel, et al.Heart Rhythm|September 5, 2021
Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic riskAlexander Burashnikov, Hector Barajas-Martinez, Robert Cox, et al.Journal of Clinical Pharmacology|July 3, 2002
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteersHenry J Pieniaszek, Sherwin K B Sy, William Ebling, et al.British Journal of Clinical Pharmacology|December 11, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteersApril M Barbour, Lea Sarov-Blat, Gengqian Cai, et al.Journal of Clinical Pharmacology|December 5, 2002
Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteersMichael J Fossler, William F Ebling, Su Ma, et al.Antimicrobial Agents and Chemotherapy|June 12, 2019
Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East AfricaSurulivelrajan Mallayasamy, Ayyappa Chaturvedula, Michael J Fossler, et al.Clinical Pharmacology in Drug Development|July 4, 2019
A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With DyslipidemiaEric J Olson, Kelly M Mahar, Thomas F Haws, et al.Pageof 5